CALIDI BIOTHERAPEUTICS INC

Calidi Biotherapeutics reports Q2 results: net loss but cutting costs, advancing RedTail immuno‑oncology candidates, and reshaping its board to drive future growth.

Calidi Biotherapeutics reveals potent pre‑clinical data for CLD‑401, its IL‑15‑armed oncolytic virus, showing strong TME immune activation and a safe profile ahead of a 2026 IND filing.

Calidi Biotherapeutics unveils its RedTail virotherapy platform, a targeted gene‑therapy breakthrough for solid tumors, advancing IL‑15 and T‑cell engagers toward clinical trials.

Calidi Biotherapeutics: a San Diego‑based clinical‑stage immuno‑oncology firm developing targeted therapies to attack solid tumors and empower the immune system, driving future cancer treatment growth.

Calidi Biotherapeutics, a clinical-stage immuno-oncology company, faces a critical crossroads as it navigates the challenges of bringing its innovative cancer treatments to market.

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with a promising mission to revolutionize cancer treatment, but its financial volatility and lack of profitability raise questions about its long-term viability.

Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company pioneering a new approach to cancer treatment by harnessing the body’s immune system to target and destroy cancer cells.

Calidi Biotherapeutics Inc. is pioneering a new era in cancer treatment with its precision genetic medicine platform, aiming to revolutionize the treatment of metastatic cancer and other conditions with unmet medical needs.